Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Large-Cell, Anaplastic 3Lymphoma 3Immunoblastic Lymphadenopathy 3Esophageal Neoplasms 3Central Nervous System Neoplasms 3Burkitt Lymphoma 3Adenocarcinoma Of Esophagus 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2Precancerous Conditions 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Gliosarcoma 2Glioblastoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Cyclophosphamide 38Paclitaxel 22Epirubicin 21Trastuzumab 20Docetaxel 20Doxorubicin 19Carboplatin 15Radiotherapy 13Taxes 11Filgrastim 11Neoadjuvant Therapy 9Bevacizumab 9Fluorouracil 8pembrolizumab 7Tamoxifen 7Albumin-Bound Paclitaxel 7Capecitabine 6pertuzumab 5Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Lapatinib 5130-nm albumin-bound paclitaxel 5pegfilgrastim 4Granulocyte Colony-Stimulating Factor 4Cisplatin 4Chemotherapy, Adjuvant 4tipifarnib 3eribulin 3Surgical Procedures, Operative 3Specimen Handling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Inflammatory Breast Neoplasms × Microarray Analysis × Clear all
NCT00017095 2013-10-24

Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
1,856 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡